JP3735379B2 - 複合体、その製造方法及びこれを含有する医薬組成物 - Google Patents

複合体、その製造方法及びこれを含有する医薬組成物 Download PDF

Info

Publication number
JP3735379B2
JP3735379B2 JP17721292A JP17721292A JP3735379B2 JP 3735379 B2 JP3735379 B2 JP 3735379B2 JP 17721292 A JP17721292 A JP 17721292A JP 17721292 A JP17721292 A JP 17721292A JP 3735379 B2 JP3735379 B2 JP 3735379B2
Authority
JP
Japan
Prior art keywords
ricin
antibody
sequence
target cell
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP17721292A
Other languages
English (en)
Japanese (ja)
Other versions
JPH05320065A (ja
Inventor
ライト，アンドリユー・フアーマン
ブラケイ，デービツド・チヤールス
フイツトン，ジヨン・エドワード
リンドホルム，リーフ
リンド，ペーター
ホルムグレン，ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Syngenta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syngenta Ltd filed Critical Syngenta Ltd
Publication of JPH05320065A publication Critical patent/JPH05320065A/ja
Application granted granted Critical
Publication of JP3735379B2 publication Critical patent/JP3735379B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Semiconductor Lasers (AREA)
  • Bipolar Transistors (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP17721292A 1991-07-03 1992-07-03 複合体、その製造方法及びこれを含有する医薬組成物 Expired - Lifetime JP3735379B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9114399:0 1991-07-03
GB919114399A GB9114399D0 (en) 1991-07-03 1991-07-03 Conjugates

Publications (2)

Publication Number Publication Date
JPH05320065A JPH05320065A (ja) 1993-12-03
JP3735379B2 true JP3735379B2 (ja) 2006-01-18

Family

ID=10697775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP17721292A Expired - Lifetime JP3735379B2 (ja) 1991-07-03 1992-07-03 複合体、その製造方法及びこれを含有する医薬組成物

Country Status (24)

Country Link
EP (1) EP0528527B1 (xx)
JP (1) JP3735379B2 (xx)
KR (1) KR100252147B1 (xx)
AT (1) ATE164768T1 (xx)
AU (1) AU665546B2 (xx)
CA (1) CA2073113C (xx)
CZ (1) CZ209792A3 (xx)
DE (1) DE69225035T2 (xx)
DK (1) DK0528527T3 (xx)
ES (1) ES2113923T3 (xx)
FI (1) FI106928B (xx)
GB (2) GB9114399D0 (xx)
GR (1) GR3026575T3 (xx)
HU (1) HU215243B (xx)
IE (1) IE922190A1 (xx)
IL (1) IL102399A (xx)
MY (1) MY110513A (xx)
NO (1) NO308539B1 (xx)
NZ (1) NZ243437A (xx)
PT (1) PT100660B (xx)
SK (1) SK209792A3 (xx)
TW (1) TW329425B (xx)
ZA (1) ZA924973B (xx)
ZW (1) ZW10192A1 (xx)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
EP0170697B1 (en) 1984-02-08 1991-10-23 Cetus Oncology Corporation Toxin conjugates
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
HU218603B (hu) * 1990-07-20 2000-10-28 Kabi Pharmacia Ab Célspecifikus antitest-szuperantigén konjugátumok és ezen készítmények előállítása

Also Published As

Publication number Publication date
IL102399A (en) 2003-05-29
PT100660A (pt) 1993-10-29
DK0528527T3 (da) 1999-01-18
IL102399A0 (en) 1993-01-14
KR100252147B1 (ko) 2000-09-01
TW329425B (en) 1998-04-11
CZ209792A3 (en) 1993-01-13
CA2073113C (en) 2004-09-14
ES2113923T3 (es) 1998-05-16
CA2073113A1 (en) 1993-01-04
DE69225035D1 (de) 1998-05-14
AU1943092A (en) 1993-01-07
HU9202219D0 (en) 1992-10-28
NZ243437A (en) 1994-10-26
FI923085A0 (fi) 1992-07-03
DE69225035T2 (de) 1998-08-13
EP0528527A3 (en) 1993-03-17
GR3026575T3 (en) 1998-07-31
HUT67048A (en) 1995-01-30
FI106928B (fi) 2001-05-15
NO922383D0 (no) 1992-06-17
KR930001928A (ko) 1993-02-22
IE922190A1 (en) 1993-01-13
EP0528527B1 (en) 1998-04-08
ATE164768T1 (de) 1998-04-15
FI923085A (fi) 1993-01-04
JPH05320065A (ja) 1993-12-03
SK209792A3 (en) 1994-06-08
GB9114399D0 (en) 1991-08-21
AU665546B2 (en) 1996-01-11
HU215243B (hu) 1998-11-30
NO922383L (no) 1993-01-04
EP0528527A2 (en) 1993-02-24
ZA924973B (en) 1993-04-28
MY110513A (en) 1998-07-31
PT100660B (pt) 1999-06-30
ZW10192A1 (en) 1993-03-31
NO308539B1 (no) 2000-09-25
GB9212880D0 (en) 1992-07-29

Similar Documents

Publication Publication Date Title
EP0170697B1 (en) Toxin conjugates
US5608039A (en) Single chain B3 antibody fusion proteins and their uses
US7153932B2 (en) Immunotoxins comprising ribosome-inactivating proteins
JP7020655B2 (ja) 組織因子標的化抗体薬物接合体
JP6326137B2 (ja) 抗ｈｅｒ２抗体及びその結合体
JP3194020B2 (ja) 腫瘍抗原特異的抗体、それを含む医薬組成物およびその抗体を産生する細胞系
US5889157A (en) Humanized B3 antibody fragments, fusion proteins, and uses thereof
US5665357A (en) Antibodies recognizing tumor associated antigen CA 55.1
JP2004115529A (ja) 悪性細胞に対する、ｏｎｃタンパク質を含む、免疫毒素
JPH07504883A (ja) リボソーム不活性化タンパク質を含む物質およびそれを調製ならびに使用する方法
AU684571B2 (en) A new ribosome-inactivating protein isolated from the plant (bryonia dioica)
Hoogenboom et al. Cloning and expression of a chimeric antibody directed against the human transferrin receptor.
US20170326249A1 (en) Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
WO1992015327A1 (en) Recombinant double chain immunotoxins
JP5014157B2 (ja) 改良免疫毒素を用いた癌治療法
US6146628A (en) Biotherapeutic agents comprising recombinant PAP and PAP mutants
EP1358318B1 (en) Hybridoma cell line g250 and its use for producing monoclonal antibodies
AU717611B2 (en) Tumor-specific antibody fragments, fusion proteins, and uses thereof
US9605075B2 (en) Hybridoma cell line G250 and its use for producing monoclonal antibodies
JP3735379B2 (ja) 複合体、その製造方法及びこれを含有する医薬組成物
KR20230135653A (ko) 항-클라우딘 18.2 항체 및 이의 항체-약물 접합체
EP1733736B1 (en) Method of producing recombinant antibodies against tumours
JP2002512774A (ja) 組換えオンコナーゼと、その化学的接合体および融合タンパク質

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20041027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050406

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20050602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050824

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20051024

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081028

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091028

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101028

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101028

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111028

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111028

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121028

Year of fee payment: 7

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121028

Year of fee payment: 7